Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Kymera Therapeutics Inc
KYMRCurrent price
33.26 USD
+0.59 USD (+1.81%)
Last closed
30.70 USD
Company
www.kymeratx.com
ISIN
US5015751044
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
2 179 524 096 USD
Yield for 12 month
-4.04 %
1Y
3Y
5Y
10Y
15Y
KYMR
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts. Address: 500 North Beacon Street, Watertown, MA, United States, 02472
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
57.67 USDP/E ratio
–Dividend Yield
–Current Year
+47 072 000 USD
Last Year
+78 592 000 USD
Current Quarter
+7 394 000 USD
Last Quarter
+3 741 000 USD
Current Year
+47 072 000 USD
Last Year
-110 489 000 USD
Current Quarter
+7 394 000 USD
Last Quarter
+1 741 000 USD
Key Figures KYMR
1 year
3 years
5 years
10 years
EBITDA
-250 736 992 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-20.65 %
PEG Ratio
–
Return On Equity TTM
-36.38 %
Wall Street Target Price
57.67 USD
Revenue TTM
47 072 000 USD
Book Value
12.88 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-84.60 %
Dividend Yield
–
Gross Profit TTM
-193 176 000 USD
Earnings per share
-2.98 USD
Diluted Eps TTM
-2.98 USD
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics KYMR
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History KYMR
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio TTM
–
Last Split Date
–
Stock Valuation KYMR
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
37.78
Price Sales TTM
46.30
Enterprise Value EBITDA
-9.49
Price Book MRQ
2.61
Financials KYMR
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators KYMR
For 52 weeks
19.45 USD
53.27 USD
50 Day MA
30.72 USD
Shares Short Prior Month
7 842 166
200 Day MA
40.92 USD
Short Ratio
11.65
Shares Short
7 990 149
Short Percent
13.73 %
BeatStart